<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02977195</url>
  </required_header>
  <id_info>
    <org_study_id>ET15-098 (NP137)</org_study_id>
    <secondary_id>2015-003907-41</secondary_id>
    <nct_id>NCT02977195</nct_id>
  </id_info>
  <brief_title>First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors</brief_title>
  <acronym>NP137</acronym>
  <official_title>NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NETRIS Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For most advanced solid tumors, current therapy is inadequate at improving quality of life,&#xD;
      slowing progression of disease, prolonging survival, and providing a cure. Hence, there is a&#xD;
      continuous need for innovative, safer and more effective anti-cancer therapies. Our study is&#xD;
      based on the dependence receptor paradigm and the associated therapeutic strategy. In&#xD;
      preclinical models, preventing Netrin-1 interaction with its receptors is sufficient to&#xD;
      trigger Netrin-1-expressing tumor cell death in vitro as well as tumor growth and metastasis&#xD;
      inhibition in vivo. This indicates that a therapeutic approach based on Netrin-1/Netrin-1&#xD;
      receptors interaction inhibition is both feasible and promising. NP137 is a &quot;first-in-class&quot;&#xD;
      humanized monoclonal antibody targeting the Netrin-1 ligand, a secreted protein recently&#xD;
      described as a driver of tumor initiation and progression. NP137 demonstrated anti-tumor&#xD;
      activity as a single agent in several pre-clinical models of cancer, including breast and&#xD;
      lung cancer. Taken together, several studies strongly support the rational for preclinical&#xD;
      development and clinical evaluation of a highly potent and selective anti-Netrin-1 antibody&#xD;
      in cancer patients. The proposed study is an open label, multicenter, Phase I dose escalation&#xD;
      study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and&#xD;
      preliminary anti-tumor activity of NP137 administered every 2 weeks (Q2W) as single agent in&#xD;
      patients with locally advanced or metastatic solid tumors. This trial will be the First in&#xD;
      Human (FIH) study for NP137; there is no clinical experience with this antibody in the&#xD;
      clinic. The study consists of 3 parts:&#xD;
&#xD;
      Part 1) a dose escalation part to define the Maximum tolerated dose and the Recommended Phase&#xD;
      II dose (MTD /RP2D) of NP137 as well as to research some PD biomarkers (Biological collection&#xD;
      cohorts) - This part is now completed with Last Patient In on December 20th 2018 - Part 2) an&#xD;
      expansion part#1 to investigate NP137 clinical activity as a single agent by collecting the&#xD;
      3-month objective response rate (ORR3m).&#xD;
&#xD;
      Part 3) an expansion part#2 to investigate NP137 clinical activity as a single agent by&#xD;
      collecting the 3-month objective response rate (ORR3m) in RH+ patients with endometrial&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose escalation part (NP137 administered as a single agent by intravenous injection with&#xD;
      7 ascending dose levels) has been initiated with an accelerated dose titration with 1 patient&#xD;
      per DL until the occurrence of a ≥ Grade 2 drug-related AE. Following the occurrence of such&#xD;
      moderate toxicity, patients have been enrolled in a slower dose escalation design with at&#xD;
      least 3 patients per DL using a Modified Continual Reassessment Method. Of note, in case no&#xD;
      toxicity occurs up to the DL4, the classical 3+3 design has been initiated. Cohorts of&#xD;
      patients with biopsable disease have been added in order to assess the impact of NP137&#xD;
      treatment on epithelial phenotype signature (assessed by RNAseq and subsequent bioinformatic&#xD;
      profiling using published E vs M score). Up to 4 additional and independent cohorts of&#xD;
      patients (n= up to 6 pts/ cohort) with biopsable disease have been enrolled. Starting from&#xD;
      DL4, the enrolment in such cohort will be allowed at highest DL that has cleared its DLT&#xD;
      assessment window. Such cohorts will allow to collect pre and on-treatment tumor biopsies in&#xD;
      order to identify PD biomarkers correlated to NP137 clinical activity.&#xD;
&#xD;
      In expansion parts, patients are treated at the RP2D defined in Part 1 (14 mg/kg).&#xD;
&#xD;
      In both parts, NP137 will continue to be administered as long as patient experience clinical&#xD;
      benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic&#xD;
      deterioration attributed to disease progression as determined by the investigator after an&#xD;
      integrated assessment of radiographic data and clinical status or withdrawal of consent or&#xD;
      patient willingness to stop the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Actual">June 2022</completion_date>
  <primary_completion_date type="Actual">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 (dose escalation part): DLT occurrence</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 14 days)</time_frame>
    <description>Dose Limiting toxicities (DLTs) are any pre-defined toxicities graded by using NCI-CTCAE v4.0 occurring during the DLT period (i.e . 28 days) and assessed as related to study drug and any other study drug related toxicity considered significant enough to be qualified as DLT in the opinion of the investigators after discussion with the sponsor. Indeed, as a principle in this first in Man study, any toxicity that the investigator or the sponsor determines to be dose-limiting, regardless of the grade, may be considered as a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (expansion part #1): Objective response rate after 3 months</measure>
    <time_frame>12 weeks of treatment (=3 months)</time_frame>
    <description>Objective response rate after 3 months (ORR3m) is defined as the rate of patients with complete response (CR) or partial response (PR) after 3 months of treatment (measurements according to RECIST 1.1 criteria).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 (expansion part #2): Objective response rate after 3 months in RH+ patients with endometrial carcinoma</measure>
    <time_frame>12 weeks of treatment (=3 months)</time_frame>
    <description>Objective response rate after 3 months (ORR3m) is defined as the rate of patients with complete response (CR) or partial response (PR) after 3 months of treatment (measurements according to RECIST 1.1 criteria).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events reporting</measure>
    <time_frame>from the date of first intake of study drug until 90 days after study drug discontinuation or at time of initiation of a new anti-cancer treatment</time_frame>
    <description>Any adverse events (AEs) graded according to NCI-CTCAE, Version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response Rate (ORR)</measure>
    <time_frame>from the date of first study drug intake until until first documented progression, assessed up to 52 weeks</time_frame>
    <description>Overall response Rate (ORR) is the proportion of evaluable patients with objective response i.e. CR or PR according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>from the time of first objective response (CR or PR as per RECIST 1.1 criteria) until first documented progression, assessed up to 52 weeks</time_frame>
    <description>Time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression or death is documented,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>from the date of first study drug intake until until first documented progression, assessed up to 52 weeks</time_frame>
    <description>Clinical Benefit Rate (CBR) is the proportion of evaluable patients with an objective response i.e. CR, PR or SD according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (for expansion part only)</measure>
    <time_frame>from the date of first study drug intake until disease progression or death, whichever occurs first, up to 52 weeks</time_frame>
    <description>Time from first study drug intake until disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS2/PFS1 (for expansion part only)</measure>
    <time_frame>From the date of first intake of previous treatment before inclusion until disease progression or death, whichever occurs first, up to 52 weeks</time_frame>
    <description>PFS2/PFS1 is defined as the ratio of the PFS of the current treatment (PFS2) versus the PFS of previous treatment before inclusion (PFS1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Growth Kinetics (growth rate)</measure>
    <time_frame>from date of progression under previous treatment before inclusion until disease progression, up to 52 weeks</time_frame>
    <description>An exploratory assessment of tumor growth kinetics will be made by comparing post-treatment scans with at least 2 pre-treatment scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the NP137 plasma concentration (AUC) versus time curve</measure>
    <time_frame>Over the first 6 cycles (each cycle is 14 days) and 30 days after last study drug intake</time_frame>
    <description>Area under the concentration-time curve from time zero to the last sample with the quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak NP137 plasma concentration (Cmax)</measure>
    <time_frame>Over the first 6 cycles (each cycle is 14 days) and 30 days after last study drug intake</time_frame>
    <description>Plasma peak concentration of NP137</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NP137 terminal elimination half-time (t1/2)</measure>
    <time_frame>Over the first 6 cycles (each cycle is 14 days) and 30 days after last study drug intake</time_frame>
    <description>Terminal elimination half-life: time required for the amount of NP137 in the body to decrease by half.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Endometrial Carcinoma</condition>
  <condition>Hormone Receptor Positive</condition>
  <arm_group>
    <arm_group_label>Dose escalation part, biological cohort and expansion Parts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and Biological Cohort: NP137 was administrated in patients with locally advanced or metastatic solid tumors Expansion Parts: NP137 was administrated in patients with locally advanced or metastatic solid tumors (Expansion part 1) and in patients with RH+ endometrial cancers (Expansion part 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP137 DL and RP2D</intervention_name>
    <description>DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg&#xD;
EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).&#xD;
FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.</description>
    <arm_group_label>Dose escalation part, biological cohort and expansion Parts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and women ≥ 18 years at time of inform consent signature.&#xD;
&#xD;
          -  For dose escalation cohorts, biological cohorts ans extension parts: Histological&#xD;
             confirmed locally advanced/metastatic solid tumors of any histological types.&#xD;
&#xD;
        For second expansion part only: patients with histologically confirmed locally advanced /&#xD;
        metastatic endometrial carcinoma and who positively expressed Hormone Receptors (with a&#xD;
        positivity threshold value ≥ 10%). Estrogene receptors (ER) and Progesterone Receptors (PR)&#xD;
        expression rates must be assessed by immunohistochemistry and fully documented.&#xD;
&#xD;
          -  Documented disease progression after at least one prior line of treatment in the&#xD;
             metastatic/advanced setting.&#xD;
&#xD;
          -  Patient must be, in the judgment of the investigator, an appropriate candidate for an&#xD;
             experimental therapy i.e. with no available curative options.&#xD;
&#xD;
          -  At least one measurable lesion as per RECIST 1.1.&#xD;
&#xD;
          -  For Expansion part only: Availability of at least 2 pre-treatment scans prior to C1D1&#xD;
             including the screening scan (i.e. within 28 days before C1D1) and the most recent&#xD;
             scan prior to screening to evaluate tumor growth kinetics.&#xD;
&#xD;
          -  Mandatory for Biological collection cohorts and Expansion part #1 and #2 only&#xD;
             (optional for dose escalation): Availability of a representative archival tumor&#xD;
             specimen in formalin-fixed paraffin embedded (FFPE) block with an associated pathology&#xD;
             report. Optional for Expansion part #2 only (RH+ endometrial carcinoma] Biopsable&#xD;
             disease i.e. at least one lesion with a diameter ≥10 mm, visible by medical imaging&#xD;
             and accessible to percutaneous sampling.&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  ECOG PS 0-1&#xD;
&#xD;
          -  Adequate hematological function: Hemoglobin ≥ 9 g/dL, Absolute neutrophil count (ANC)&#xD;
             ≥ 1.5 x 109/L, Platelet count ≥ 100 x 109/L (without transfusion within 21 days before&#xD;
             C1D1).&#xD;
&#xD;
          -  Adequate renal function: Calculated creatinine clearance by MDRD or CDK-EPI ≥50&#xD;
             mL/min/1.73m2 or serum creatinine ≤ 1.5 ULN&#xD;
&#xD;
          -  Adequate liver function: AST and ALT ≤ 2.5 ULN (up to 5 ULN may be tolerated in case&#xD;
             of liver metastases), Total serum bilirubin ≤ 1.5 x ULN (except for patients with&#xD;
             Gilbert disease for whom a total serum bilirubin ≤3mg/dL is acceptable).&#xD;
&#xD;
          -  Adequate coagulation function: INR≤ 1.5, aPTT≤ 1.5 ULN.&#xD;
&#xD;
          -  Adequate cardiovascular function: QTc ≤470ms, Resting BP systolic &lt;160mmHg and&#xD;
             diastolic&lt;100mmHg, LVEF ≥50% as determined by multiple-gated acquisition (MUGA) scan&#xD;
             or transthoracic echocardiogram&#xD;
&#xD;
          -  Minimal wash-out period for prior treatment before C1D1: For chemotherapy, tyrosine&#xD;
             kinase inhibitor &gt; 2 weeks, Radiation therapy &gt;4 weeks, For monoclonal antibodies &gt;4&#xD;
             weeks, For immunosuppressive medication &gt; 2 weeks, with the exceptions of intranasal&#xD;
             and inhaled corticosteroids or systemic corticosteroids at doses which are not to&#xD;
             exceed 10 mg/day of prednisone, or an equivalent corticosteroid, Major surgery &gt;4&#xD;
             weeks, For hormonotherapy &gt; 2 weeks with exception of GnRH analogs for prostate cancer&#xD;
             patients who should continue on GnRH analogs throughout the study.&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative serum pregnancy test at&#xD;
             screening (7 days before C1D1).&#xD;
&#xD;
          -  Women of child-bearing potential must agree to remain abstinent or to use 2 effective&#xD;
             forms of contraception from the time of the negative pregnancy test up to 3 months&#xD;
             after the last dose of study drug. Effective forms of contraception are listed in&#xD;
             Protocol.&#xD;
&#xD;
          -  Men must agree to remain abstinent or to use an effective contraceptive method during&#xD;
             the study and for up to 3 months after the last dose of study drug&#xD;
&#xD;
          -  Patient should understand, sign, and date the written voluntary informed consent form&#xD;
             prior to any protocol-specific procedures.&#xD;
&#xD;
          -  Patient should be able and willing to comply with study visits and procedures as per&#xD;
             protocol.&#xD;
&#xD;
          -  Patients must be covered by a medical insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persistence of CTCAE ≥ Grade 2 toxicity due to prior anti-cancer therapy (except&#xD;
             alopecia (any grades), blood tests values according to inclusion criteria, Grade ≥3&#xD;
             peripheral neuropathy.&#xD;
&#xD;
          -  History of severe allergic anaphylactic reactions to one of the components of the&#xD;
             study drug or to humanized mAbs&#xD;
&#xD;
          -  Any known neurodegenerative (Alzheimer's disease, Parkinson's disease and related&#xD;
             disorders, amyotrophic lateral sclerosis, prion disease, motor neuron diseases,&#xD;
             Huntington's disease, spinocerebellar ataxia, spinal muscular atrophy,) or&#xD;
             neuroinflammatory disease (multiple sclerosis, …).&#xD;
&#xD;
          -  Active or untreated CNS metastases. Patients with radiographically stable,&#xD;
             asymptomatic previously irradiated lesions are eligible provided that patient is ≥ 4&#xD;
             weeks beyond completion of cranial irradiation and ≥ 3 weeks off of corticosteroid&#xD;
             therapy are eligible.&#xD;
&#xD;
          -  Any uncontrolled intercurrent illness that would limit compliance with protocol&#xD;
             requirements including, but not limited to: Ongoing or active infection including&#xD;
             acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV),&#xD;
             History of chronic liver disease or hepatic cirrhosis, Impaired cardiovascular&#xD;
             function or clinically significant cardiovascular diseases including but not limited&#xD;
             to symptomatic congestive heart failure, history of acute myocardial infection, acute&#xD;
             coronary syndromes; history or current evidence of clinically significant cardiac&#xD;
             arrhythmia and/or conduction abnormality within 6 months prior to C1D1, Psychiatric&#xD;
             illness / specific social situations.&#xD;
&#xD;
          -  Other invasive malignancy in the last 2 years except for those with a minimal risk of&#xD;
             metastasis or death such as adequately managed in-situ carcinoma of the cervix, basal&#xD;
             or squamous cell skin cancer, localized prostate cancer or ductal carcinoma in situ&#xD;
             treated with curative intent.&#xD;
&#xD;
          -  Needs to be treated with a forbidden concomitant/concurrent therapies/procedures&#xD;
             including: Any investigational anticancer therapy other than the study drug , Any&#xD;
             concurrent chemotherapy, radiotherapy (except palliative radiotherapy performed on&#xD;
             non-target lesion and following sponsor's approval), immunotherapy, biologic or&#xD;
             hormonal therapy* for cancer treatment. *: for prostate cancer patients, treatment&#xD;
             with GnrH analogs is allowed, Immunosuppressive medications including methotrexate,&#xD;
             azathioprine, and TNF-α blockers. Use of immunosuppressive medications including&#xD;
             steroids for the management of AEs or in subjects with contrast allergies is&#xD;
             acceptable, Major surgery, Any hematopoietic growth factor (during the DLT period)&#xD;
&#xD;
          -  Female subjects who are pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe CASSIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico - Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT-Oncopôle de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>November 25, 2016</study_first_submitted>
  <study_first_submitted_qc>November 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>July 22, 2022</last_update_submitted>
  <last_update_submitted_qc>July 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in Human</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Netrin-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02977195
org study id: ET15-098 (NP137)
secondary id: 2015-003907-41
nct id: NCT02977195
lead sponsor: 
collaborator: 
has dmc: Yes
For most advanced solid tumors, current therapy is inadequate at improving quality of life,
      slowing progression of disease, prolonging survival, and providing a cure. Hence, there is a
      continuous need for innovative, safer and more effective anti-cancer therapies. Our study is
      based on the dependence receptor paradigm and the associated therapeutic strategy. In
      preclinical models, preventing Netrin-1 interaction with its receptors is sufficient to
      trigger Netrin-1-expressing tumor cell death in vitro as well as tumor growth and metastasis
      inhibition in vivo. This indicates that a therapeutic approach based on Netrin-1/Netrin-1
      receptors interaction inhibition is both feasible and promising. NP137 is a "first-in-class"
      humanized monoclonal antibody targeting the Netrin-1 ligand, a secreted protein recently
      described as a driver of tumor initiation and progression. NP137 demonstrated anti-tumor
      activity as a single agent in several pre-clinical models of cancer, including breast and
      lung cancer. Taken together, several studies strongly support the rational for preclinical
      development and clinical evaluation of a highly potent and selective anti-Netrin-1 antibody
      in cancer patients. The proposed study is an open label, multicenter, Phase I dose escalation
      study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and
      preliminary anti-tumor activity of NP137 administered every 2 weeks (Q2W) as single agent in
      patients with locally advanced or metastatic solid tumors. This trial will be the First in
      Human (FIH) study for NP137; there is no clinical experience with this antibody in the
      clinic. The study consists of 3 parts:

      Part 1) a dose escalation part to define the Maximum tolerated dose and the Recommended Phase
      II dose (MTD /RP2D) of NP137 as well as to research some PD biomarkers (Biological collection
      cohorts) - This part is now completed with Last Patient In on December 20th 2018 - Part 2) an
      expansion part#1 to investigate NP137 clinical activity as a single agent by collecting the
      3-month objective response rate (ORR3m).

      Part 3) an expansion part#2 to investigate NP137 clinical activity as a single agent by
      collecting the 3-month objective response rate (ORR3m) in RH+ patients with endometrial
      carcinoma.
The dose escalation part (NP137 administered as a single agent by intravenous injection with
      7 ascending dose levels) has been initiated with an accelerated dose titration with 1 patient
      per DL until the occurrence of a ≥ Grade 2 drug-related AE. Following the occurrence of such
      moderate toxicity, patients have been enrolled in a slower dose escalation design with at
      least 3 patients per DL using a Modified Continual Reassessment Method. Of note, in case no
      toxicity occurs up to the DL4, the classical 3+3 design has been initiated. Cohorts of
      patients with biopsable disease have been added in order to assess the impact of NP137
      treatment on epithelial phenotype signature (assessed by RNAseq and subsequent bioinformatic
      profiling using published E vs M score). Up to 4 additional and independent cohorts of
      patients (n= up to 6 pts/ cohort) with biopsable disease have been enrolled. Starting from
      DL4, the enrolment in such cohort will be allowed at highest DL that has cleared its DLT
      assessment window. Such cohorts will allow to collect pre and on-treatment tumor biopsies in
      order to identify PD biomarkers correlated to NP137 clinical activity.

      In expansion parts, patients are treated at the RP2D defined in Part 1 (14 mg/kg).

      In both parts, NP137 will continue to be administered as long as patient experience clinical
      benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic
      deterioration attributed to disease progression as determined by the investigator after an
      integrated assessment of radiographic data and clinical status or withdrawal of consent or
      patient willingness to stop the treatment.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Part 1 (dose escalation part): DLT occurrence
time frame: At the end of Cycle 2 (each cycle is 14 days)
description: Dose Limiting toxicities (DLTs) are any pre-defined toxicities graded by using NCI-CTCAE v4.0 occurring during the DLT period (i.e . 28 days) and assessed as related to study drug and any other study drug related toxicity considered significant enough to be qualified as DLT in the opinion of the investigators after discussion with the sponsor. Indeed, as a principle in this first in Man study, any toxicity that the investigator or the sponsor determines to be dose-limiting, regardless of the grade, may be considered as a DLT.
measure: Part 2 (expansion part #1): Objective response rate after 3 months
time frame: 12 weeks of treatment (=3 months)
description: Objective response rate after 3 months (ORR3m) is defined as the rate of patients with complete response (CR) or partial response (PR) after 3 months of treatment (measurements according to RECIST 1.1 criteria).
measure: Part 3 (expansion part #2): Objective response rate after 3 months in RH+ patients with endometrial carcinoma
time frame: 12 weeks of treatment (=3 months)
description: Objective response rate after 3 months (ORR3m) is defined as the rate of patients with complete response (CR) or partial response (PR) after 3 months of treatment (measurements according to RECIST 1.1 criteria).
measure: Adverse events reporting
time frame: from the date of first intake of study drug until 90 days after study drug discontinuation or at time of initiation of a new anti-cancer treatment
description: Any adverse events (AEs) graded according to NCI-CTCAE, Version 4.03.
measure: Overall response Rate (ORR)
time frame: from the date of first study drug intake until until first documented progression, assessed up to 52 weeks
description: Overall response Rate (ORR) is the proportion of evaluable patients with objective response i.e. CR or PR according to RECIST 1.1.
measure: Duration of Response (DoR)
time frame: from the time of first objective response (CR or PR as per RECIST 1.1 criteria) until first documented progression, assessed up to 52 weeks
description: Time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression or death is documented,
measure: Clinical Benefit Rate (CBR)
time frame: from the date of first study drug intake until until first documented progression, assessed up to 52 weeks
description: Clinical Benefit Rate (CBR) is the proportion of evaluable patients with an objective response i.e. CR, PR or SD according to RECIST 1.1.
measure: Progression-free survival (for expansion part only)
time frame: from the date of first study drug intake until disease progression or death, whichever occurs first, up to 52 weeks
description: Time from first study drug intake until disease progression or death, whichever occurs first
measure: PFS2/PFS1 (for expansion part only)
time frame: From the date of first intake of previous treatment before inclusion until disease progression or death, whichever occurs first, up to 52 weeks
description: PFS2/PFS1 is defined as the ratio of the PFS of the current treatment (PFS2) versus the PFS of previous treatment before inclusion (PFS1).
measure: Tumor Growth Kinetics (growth rate)
time frame: from date of progression under previous treatment before inclusion until disease progression, up to 52 weeks
description: An exploratory assessment of tumor growth kinetics will be made by comparing post-treatment scans with at least 2 pre-treatment scans.
measure: Area under the NP137 plasma concentration (AUC) versus time curve
time frame: Over the first 6 cycles (each cycle is 14 days) and 30 days after last study drug intake
description: Area under the concentration-time curve from time zero to the last sample with the quantifiable concentration.
measure: Peak NP137 plasma concentration (Cmax)
time frame: Over the first 6 cycles (each cycle is 14 days) and 30 days after last study drug intake
description: Plasma peak concentration of NP137
measure: NP137 terminal elimination half-time (t1/2)
time frame: Over the first 6 cycles (each cycle is 14 days) and 30 days after last study drug intake
description: Terminal elimination half-life: time required for the amount of NP137 in the body to decrease by half.
arm group label: Dose escalation part, biological cohort and expansion Parts
arm group type: Experimental
description: Dose Escalation and Biological Cohort: NP137 was administrated in patients with locally advanced or metastatic solid tumors Expansion Parts: NP137 was administrated in patients with locally advanced or metastatic solid tumors (Expansion part 1) and in patients with RH+ endometrial cancers (Expansion part 2)
intervention type: Drug
intervention name: NP137 DL and RP2D
description: DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg
EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).
FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
arm group label: Dose escalation part, biological cohort and expansion Parts
criteria: 
gender: Female
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Philippe CASSIER, MD
role: Principal Investigator
affiliation: Centre Leon Berard
facility: 
facility: 
facility: 
country: France
responsible party type: Sponsor
mesh term: Endometrial Neoplasms
sharing ipd: No